About Acura Pharmaceuticals (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:ACUR
- CUSIP: 00509L70
- Web: acurapharm.com
- Market Cap: $8.58 million
- Outstanding Shares: 20,795,000
- 50 Day Moving Avg: $0.45
- 200 Day Moving Avg: $0.50
- 52 Week Range: $0.40 - $1.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 1.12
- P/E Growth: 0.0000
- Annual Revenue: $6.79 million
- Price / Sales: 1.26
- Book Value: ($0.03) per share
- Price / Book: -15.29
- EBITDA: ($1,420,000.00)
- Net Margins: -2,335.87%
- Return on Equity: -1,237.56%
- Return on Assets: -114.20%
- Debt-to-Equity Ratio: -7.29%
- Current Ratio: 1.25%
- Quick Ratio: 1.15%
- Average Volume: 11,534 shs.
- Beta: 2.12
- Short Ratio: 0.73
Frequently Asked Questions for Acura Pharmaceuticals (NASDAQ:ACUR)
What is Acura Pharmaceuticals' stock symbol?
Acura Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACUR."
How were Acura Pharmaceuticals' earnings last quarter?
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted its earnings results on Monday, August, 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.07. The firm earned $0.09 million during the quarter. Acura Pharmaceuticals had a negative net margin of 2,335.87% and a negative return on equity of 1,237.56%. View Acura Pharmaceuticals' Earnings History.
Where is Acura Pharmaceuticals' stock going? Where will Acura Pharmaceuticals' stock price be in 2017?
0 equities research analysts have issued twelve-month target prices for Acura Pharmaceuticals' shares. Their forecasts range from $10,000,000.00 to $0.00. On average, they anticipate Acura Pharmaceuticals' share price to reach $0.00 in the next twelve months. View Analyst Ratings for Acura Pharmaceuticals.
Who are some of Acura Pharmaceuticals' key competitors?
Some companies that are related to Acura Pharmaceuticals include Senestech (SNES), Soligenix (SNGX), Alliqua BioMedical (ALQA), Novogen Limited (NVGN), Transgenomic (PRPO), Galena Biopharma (GALE), Valeritas Holdings (VLRX), CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF), Tandem Diabetes Care (TNDM), Opexa Therapeutics (ACER), Jaguar Animal Health (JAGX), Immune Pharmaceuticals (IMNP), Lombard Medical (EVAR), Dynatronics Corporation (DYNT), Kitov Pharmaceuticals Holdings (KTOV), Argos Therapeutics (ARGS), Relmada Therapeutics (RLMDD) and Avinger (AVGR).
Who are Acura Pharmaceuticals' key executives?
Acura Pharmaceuticals' management team includes the folowing people:
- Robert B. Jones, President, Chief Executive Officer, Director
- Peter A. Clemens, Chief Financial Officer, Senior Vice President, Secretary
- Robert A. Seiser CPA, Vice President, Corporate Controller and Treasurer
- J. Bradley Rivet, Vice President - Marketing
- Albert W. Brzeczko Ph.D., Vice President -Technical Affairs
- James F. Emigh, Vice President - Corporate Development
- George K. Ross, Independent Director
- William G. Skelly, Independent Director
- Immanuel Thangaraj, Independent Director
- Bruce F. Wesson, Independent Director
Who owns Acura Pharmaceuticals stock?
How do I buy Acura Pharmaceuticals stock?
Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acura Pharmaceuticals' stock price today?
MarketBeat Community Rating for Acura Pharmaceuticals (NASDAQ ACUR)MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.41.
Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Acura Pharmaceuticals (NASDAQ:ACUR)
Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/21/2016||FBR & Co||Reiterated Rating||Outperform||$10.00||N/A|
|10/18/2016||Roth Capital||Set Price Target||Buy||$6.00||N/A|
Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)Earnings History by Quarter for Acura Pharmaceuticals (NASDAQ ACUR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2017||Q2 2017||($0.11)||($0.18)||$0.09 million||View||N/A|
|5/12/2017||Q1 2017||($0.11)||$0.03||$0.34 million||$2.72 million||View||N/A|
|11/14/2016||Q3||($0.27)||($0.19)||$0.23 million||$0.22 million||View||N/A|
|8/8/2016||Q2||($0.28)||($0.28)||$0.19 million||$0.26 million||View||N/A|
|5/2/2016||Q116||($0.26)||($0.28)||$0.15 million||$0.22 million||View||N/A|
|2/29/2016||Q315||($0.03)||($0.08)||$2.70 million||$2.68 million||View||Listen|
|8/3/2015||Q215||($0.02)||($0.05)||$2.90 million||$0.34 million||View||N/A|
|5/4/2015||Q115||$0.07||$0.03||$7.60 million||$5.40 million||View||N/A|
|3/2/2015||Q414||($0.09)||($0.06)||$0.05 million||$0.53 million||View||N/A|
|11/3/2014||Q3 2014||($0.08)||($0.06)||$0.05 million||$0.15 million||View||N/A|
Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
Current Year EPS Consensus Estimate: $-0.4600 EPS
Next Year EPS Consensus Estimate: $0.3700 EPS
Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Ownership Percentage: 7.40%Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Institutional Ownership Percentage: 31.23%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/29/2017||Albert W Brzeczko||VP||Buy||10,800||$0.47||$5,076.00|| |
|6/17/2015||Claudius Llc||Major Shareholder||Sell||104,823||$1.08||$113,208.84|| |
|1/12/2015||Claudius Llc||Major Shareholder||Sell||171,000||$0.62||$106,020.00|| |
|5/22/2014||William G Skelly||Director||Sell||4,600||$1.23||$5,658.00|| |
|5/20/2014||William G Skelly||Director||Sell||5,000||$1.21||$6,050.00|| |
|5/19/2014||Albert W Brzeczko||VP||Buy||2,000||$1.20||$2,400.00|| |
|5/16/2014||Bruce F Wesson||Director||Buy||80,000||$1.13||$90,400.00|| |
|5/16/2014||James F Emigh||VP||Buy||15,000||$1.21||$18,150.00|| |
|5/16/2014||Peter A Clemens||CFO||Buy||3,000||$1.21||$3,630.00|| |
|5/14/2014||William G Skelly||Director||Sell||2,900||$1.21||$3,509.00|| |
|5/12/2014||William G Skelly||Director||Sell||5,000||$1.25||$6,250.00|| |
|5/8/2014||William G Skelly||Director||Sell||2,500||$1.30||$3,250.00|| |
|3/3/2014||Claudius Llc||Major Shareholder||Sell||2,500||$2.00||$5,000.00|| |
|2/28/2014||Claudius Llc||Major Shareholder||Sell||351,260||$2.02||$709,545.20|| |
|2/24/2014||Claudius Llc||Major Shareholder||Sell||44,019||$1.97||$86,717.43|| |
|11/25/2013||Albert W Brzeczko||VP||Buy||1,215||$1.70||$2,065.50|| |
|10/10/2013||Claudius Llc||Major Shareholder||Sell||4,200||$2.05||$8,610.00|| |
|8/27/2013||William G Skelly||Director||Sell||2,000||$1.55||$3,100.00|| |
|7/15/2013||Care Capital Ii Llc||Major Shareholder||Sell||31,610||$2.04||$64,484.40|| |
|7/3/2013||Care Capital Ii Llc||Major Shareholder||Sell||14,200||$2.00||$28,400.00|| |
|7/2/2013||Claudius Llc||Major Shareholder||Sell||200,000||$2.15||$430,000.00|| |
|6/27/2013||Care Capital Ii Llc||Major Shareholder||Sell||76,281||$2.01||$153,324.81|| |
|6/24/2013||Care Capital Ii Llc||Major Shareholder||Sell||83,000||$2.03||$168,490.00|| |
|6/19/2013||Care Capital Ii Llc||Major Shareholder||Sell||114,000||$2.12||$241,680.00|| |
|6/17/2013||Claudius Llc||Major Shareholder||Sell||20,446||$2.15||$43,958.90|| |
|6/14/2013||Care Capital Ii Llc||Major Shareholder||Sell||90,000||$2.16||$194,400.00|| |
|6/11/2013||Care Capital Ii Llc||Major Shareholder||Sell||102,000||$2.19||$223,380.00|| |
|6/10/2013||Claudius Llc||Major Shareholder||Sell||21,496||$2.20||$47,291.20|| |
|6/6/2013||Claudius Llc||Major Shareholder||Sell||39,453||$2.19||$86,402.07|| |
|6/3/2013||Care Capital Ii Llc||Major Shareholder||Sell||148,000||$2.24||$331,520.00|| |
|5/31/2013||Claudius Llc||Major Shareholder||Sell||31,559||$2.25||$71,007.75|| |
|5/29/2013||Care Capital Ii Llc||Major Shareholder||Sell||108,701||$2.33||$253,273.33|| |
|5/28/2013||William G Skelly||Director||Sell||2,000||$2.40||$4,800.00|| |
|5/23/2013||Care Capital Ii Llc||Major Shareholder||Sell||252,000||$2.31||$582,120.00|| |
|5/22/2013||William G Skelly||Director||Sell||4,000||$2.33||$9,320.00|| |
|5/21/2013||Claudius Llc||Major Shareholder||Sell||47,410||$2.30||$109,043.00|| |
|5/20/2013||Care Capital Ii Llc||Major Shareholder||Sell||510,000||$2.36||$1,203,600.00|| |
|5/16/2013||Care Capital Ii Llc||Major Shareholder||Sell||662,000||$2.38||$1,575,560.00|| |
|5/16/2013||William G Skelly||Director||Sell||3,000||$2.25||$6,750.00|| |
|5/15/2013||Claudius Llc||Major Shareholder||Sell||183,434||$2.33||$427,401.22|| |
|5/13/2013||Care Capital Ii Llc||Major Shareholder||Sell||259,000||$2.19||$567,210.00|| |
|5/9/2013||William G Skelly||Director||Sell||3,000||$2.20||$6,600.00|| |
|4/11/2013||Claudius Llc||Major Shareholder||Sell||121,454||$2.23||$270,842.42|| |
|3/26/2013||Care Capital Ii Llc||Major Shareholder||Sell||39,554||$2.17||$85,832.18|| |
Headline Trends for Acura Pharmaceuticals (NASDAQ:ACUR)
Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
Loading headlines, please wait.
Acura Pharmaceuticals (ACUR) Chart for Sunday, October, 22, 2017